Dr. Jie Tian is the founder and chief scientist of the Key Laboratory of Molecular Imaging, Chinese Academy of Sciences. His research interests are in the development and clinical translation of optical multimodality molecular imaging technologies and medical image artificial intelligence (AI) technologies. Dr. Tian is a pioneer in the field of molecular imaging in China and has an international reputation. He is the Fellow of WMIS, AAAS, IEEE, AIMBE, IAMBE, SPIE, OSA, ISMRM, and IAPR. He is a founding member of the Chinese Society for Molecular Imaging (CSMI). He served as its first president (2010-2017). He also serves as the editorial board member of Molecular Imaging and Biology, IEEE Transactions on Medical Imaging, IEEE Transactions on Biomedical Engineering, IEEE Journal of Biomedical and Health Informatics, European Radiology, and he serves as the editor-in-chief of Visual Computing for Industry, Biomedicine and Art published by Springer. As the first/co-first author or corresponding/co-corresponding author, he has published more than 300 peer-reviewed articles, including 16 in Nature and Science series journals, over 100 technological studies in IEEE Transaction series journals, and over 80 clinical studies in various clinical research journals. His work has received more than 82,554 citations with H-index of 126. He has been consecutively selected as the Global Most Cited Researchers listed by Clarivate for the last four years (2021-2024). Dr. Jie Tian holds 30 U.S. patents and more than 170 China patents in the field of optical molecular imaging and magnetic particle imaging. Seven patents of these have successfully achieved industrial translation. Moreover, he has mentored over 60 Ph.D. in biomedical engineering and has published over 10 academic textbooks.Dr. Tian has achieved numerous pioneering advancements in the field of cancer molecular imaging and successfully commercialized these technical progressions. His work has greatly enhanced the precision of tumor surgeries, while uplifted the standards of surgical practices in primary hospitals. By making these significant improvements, Dr. Tian has been invited to publish on high-profile journals, such as Nature Reviews Bioengineering (2023) and Nature Reviews Clinical Oncology (2024), leading to a remarkable influence in the global academic arena. 

For more information about Dr. Tian, please visit his other websites: 
     http://www.3dmed.net/ 
     http://www.mitk.net.cn/ 

     http://mpilab.net/ 
     http://www.radiomics.net.cn/ 
Email:  tian@ieee.org